Why Palantir Technologies Stock Charged Higher Today Yahoo Finance

Image source: The Motley Fool. Tuesday, Feb. 3, 2026 at 8:30 a.m. ET Call participants Founder and CEO — Michael Novogratz President and Head of Asset Management — Christopher Ferraro Chief Financial Officer — Anthony Paquette Need a quote from a Motley Fool analyst? Email [email protected] Takeaways GAAP Net Loss -- $241 million, or $0.61 per share, with approximately $160 million attributable to one-time items including mining infrastructure write-downs, US listing and reorganization costs, and a negative mark-to-market on exchangeable notes. -- $241 million, or $0.61 per share, with approximately $160 million attributable to one-time items including mining infrastructure write-downs, US listing and reorganization costs, and a negative mark-to-market on exchangeable notes. Adjusted EBITDA -- $34 million, achieved despite a 10% decline in total crypto market capitalization and a 24% drop in digital asset prices in the fourth quarter. -- $34 million, achieved despite a 10% decline in total crypto market capitalization and a 24% drop in digital asset prices in the fourth quarter. Digital Assets Segment Adjusted Gross Profit -- $5 million, up 67% year over year, with broad-based growth across trading, investment banking, lending, asset management, and staking. -- $5 million, up 67% year over year, with broad-based growth across trading, investment banking, lending, asset management, and staking. Global Markets Adjusted Gross Profit -- $423 million for the year, up 88% year over year; $30 million delivered in Q4 alone. -- $423 million for the year, up 88% year over year; $30 million delivered in Q4 alone. Record Trading Volumes and Loan Book Growth -- Record level of trading activity noted, with the average loan book at $1.8 billion in Q4, up slightly versus Q3, despite a sharp 24%-25% industry asset price decline. -- Record level of trading activity noted, with the average loan book at $1.8 billion in Q4, up slightly versus Q3, despite a sharp 24%-25% industry asset p...

Investors considering a purchase of Quanta Services, Inc. (Symbol: PWR) shares, but cautious about paying the going market price of $487.57/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $310 strike, which has a bid at the time of this writing of $21.50. Collecting that bid as the premium represents a 6.9% return against the $310 commitment, or a 3.5% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to PWR's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $310 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Quanta Services, Inc. sees its shares fall 36.1% and the contract is exercised (resulting in a cost basis of $288.50 per share before broker commissions, subtracting the $21.50 from $310), the only upside to the put seller is from collecting that premium for the 3.5% annualized rate of return. Interestingly, that annualized 3.5% figure actually exceeds the 0.1% annualized dividend paid by Quanta Services, Inc. by 3.4%, based on the current share price of $487.57. And yet, if an investor was to buy the stock at the going market price in order to collect the dividend, there is greater downside because the stock would have to lose 36.13% to reach the $310 strike price. Always important when discussing dividends is the fact that, in general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Quanta Services, Inc., looking at the dividend history chart for PWR below can help in...

Brent Thill, an analyst at Jefferies, made a compelling case for Amazon (AMZN) stock ahead of the company's earnings report this week. His argument is straightforward: Amazon's stock is trading cheaply, and most investors are missing it. The Valuation Disconnect According to Thill, Amazon currently trades at 13 times next-twelve-month enterprise value to EBITDA. It means that investors are paying significantly less for Amazon's profits than they have historically. The discount is striking. Amazon trades six turns below its 10-year average and a full eight turns below Walmart, according to Thill's analysis. For a company with Amazon's growth profile and multiple revenue streams, that's unusual. "We think that's too cheap at the early stage of AWS re-acceleration," Thill wrote in his note to clients. The stock trades at a 25% discount compared to major internet peers. That's a meaningful gap for a company that dominates e-commerce, leads in cloud computing, and continues to expand into advertising and other high-margin businesses. AWS Is Ready to Accelerate The biggest catalyst Thill sees is Amazon Web Services (AWS). The server juggernaut generated $33 billion in revenue last quarter, growing 20.2% year-over-year (YoY). That marked the fastest growth rate in 11 quarters and represented a 270-basis-point acceleration from the prior quarter. But Thill believes the real story is just beginning. He points to three specific drivers that could push AWS backlog growth into the mid-20s percentage range or higher in the fourth quarter. First, AWS faces its easiest YoY comparison in the fourth quarter of 2025. Second, October bookings alone surpassed the entire third quarter's deal volume. That includes a massive $38 billion contract with OpenAI that wasn't even reflected in the third quarter backlog of $200 billion. Third, industry checks across the board indicate bullish sentiment toward cloud spending. Companies want to run their AI workloads on AWS because of its superior ...

Investors eyeing a purchase of Coinbase Global Inc (Symbol: COIN) shares, but cautious about paying the going market price of $181.50/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December 2028 put at the $100 strike, which has a bid at the time of this writing of $21.65. Collecting that bid as the premium represents a 21.6% return against the $100 commitment, or a 7.5% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to COIN's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $100 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Coinbase Global Inc sees its shares fall 45% and the contract is exercised (resulting in a cost basis of $78.35 per share before broker commissions, subtracting the $21.65 from $100), the only upside to the put seller is from collecting that premium for the 7.5% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Coinbase Global Inc, and highlighting in green where the $100 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the December 2028 put at the $100 strike for the 7.5% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Coinbase Global Inc (considering the last 251 trading day closing values as well as today's price of $181.50) to be 71%. For other put options contract ideas at the various different ...

Investors eyeing a purchase of Centene Corp (Symbol: CNC) stock, but tentative about paying the going market price of $42.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $20 strike, which has a bid at the time of this writing of $1.20. Collecting that bid as the premium represents a 6% return against the $20 commitment, or a 3% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to CNC's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $20 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Centene Corp sees its shares decline 53.3% and the contract is exercised (resulting in a cost basis of $18.80 per share before broker commissions, subtracting the $1.20 from $20), the only upside to the put seller is from collecting that premium for the 3% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Centene Corp, and highlighting in green where the $20 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2028 put at the $20 strike for the 3% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Centene Corp (considering the last 251 trading day closing values as well as today's price of $42.69) to be 68%. For other put options contract ideas at the various different available expirations, visit the CNC Stock Opt...

Investors eyeing a purchase of Gartner Inc (Symbol: IT) stock, but tentative about paying the going market price of $153.47/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $140 strike, which has a bid at the time of this writing of $9.20. Collecting that bid as the premium represents a 6.6% return against the $140 commitment, or a 17.8% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to IT's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $140 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Gartner Inc sees its shares decline 9% and the contract is exercised (resulting in a cost basis of $130.80 per share before broker commissions, subtracting the $9.20 from $140), the only upside to the put seller is from collecting that premium for the 17.8% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Gartner Inc, and highlighting in green where the $140 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the June put at the $140 strike for the 17.8% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Gartner Inc (considering the last 251 trading day closing values as well as today's price of $153.47) to be 54%. For other put options contract ideas at the various different available expirations, visit the IT Stock Options p...

Investors eyeing a purchase of GE HealthCare Technologies Inc (Symbol: GEHC) shares, but tentative about paying the going market price of $79.68/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $50 strike, which has a bid at the time of this writing of $2.00. Collecting that bid as the premium represents a 4% return against the $50 commitment, or a 2% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to GEHC's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $50 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless GE HealthCare Technologies Inc sees its shares decline 37.6% and the contract is exercised (resulting in a cost basis of $48.00 per share before broker commissions, subtracting the $2.00 from $50), the only upside to the put seller is from collecting that premium for the 2% annualized rate of return. Worth considering, is that the annualized 2% figure actually exceeds the 0.2% annualized dividend paid by GE HealthCare Technologies Inc by 1.8%, based on the current share price of $79.68. And yet, if an investor was to buy the stock at the going market price in order to collect the dividend, there is greater downside because the stock would have to lose 37.57% to reach the $50 strike price. Always important when discussing dividends is the fact that, in general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of GE HealthCare Technologies Inc, looking at the dividend history c...

诺和诺德美国存托股(ADRS)因待发布消息而暂停交易。(财联社) 免责声明： 风险提示：本文内容仅供参考，不代表同花顺观点。同花顺各类信息服务基于人工智能算法，如有出入请以证监会指定上市公司信息披露平台为准。如有投资者据此操作，风险自担，同花顺对此不承担任何责任。

Investors considering a purchase of Eli Lilly (Symbol: LLY) shares, but cautious about paying the going market price of $1033.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $750 strike, which has a bid at the time of this writing of $62.20. Collecting that bid as the premium represents a 8.3% return against the $750 commitment, or a 4.2% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to LLY's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $750 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Eli Lilly sees its shares fall 28.1% and the contract is exercised (resulting in a cost basis of $687.80 per share before broker commissions, subtracting the $62.20 from $750), the only upside to the put seller is from collecting that premium for the 4.2% annualized rate of return. Interestingly, that annualized 4.2% figure actually exceeds the 0.7% annualized dividend paid by Eli Lilly by 3.5%, based on the current share price of $1033.37. And yet, if an investor was to buy the stock at the going market price in order to collect the dividend, there is greater downside because the stock would have to lose 28.07% to reach the $750 strike price. Always important when discussing dividends is the fact that, in general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Eli Lilly, looking at the dividend history chart for LLY below can help in judging whether the most recent dividend is l...

Investors eyeing a purchase of Deckers Outdoor Corp. (Symbol: DECK) stock, but cautious about paying the going market price of $113.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $50 strike, which has a bid at the time of this writing of $2.40. Collecting that bid as the premium represents a 4.8% return against the $50 commitment, or a 2.4% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to DECK's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $50 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Deckers Outdoor Corp. sees its shares decline 55.6% and the contract is exercised (resulting in a cost basis of $47.60 per share before broker commissions, subtracting the $2.40 from $50), the only upside to the put seller is from collecting that premium for the 2.4% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Deckers Outdoor Corp., and highlighting in green where the $50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2028 put at the $50 strike for the 2.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Deckers Outdoor Corp. (considering the last 251 trading day closing values as well as today's price of $113.17) to be 56%. For other put options contract ideas at the various different...

Think Palantir's blistering growth is over? Think again MSN

Investors eyeing a purchase of Molina Healthcare Inc (Symbol: MOH) shares, but cautious about paying the going market price of $181.98/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $75 strike, which has a bid at the time of this writing of $4.50. Collecting that bid as the premium represents a 6% return against the $75 commitment, or a 3% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to MOH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $75 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Molina Healthcare Inc sees its shares decline 59.2% and the contract is exercised (resulting in a cost basis of $70.50 per share before broker commissions, subtracting the $4.50 from $75), the only upside to the put seller is from collecting that premium for the 3% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Molina Healthcare Inc, and highlighting in green where the $75 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2028 put at the $75 strike for the 3% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Molina Healthcare Inc (considering the last 251 trading day closing values as well as today's price of $181.98) to be 56%. For other put options contract ideas at the various different availabl...

Investors eyeing a purchase of Advanced Micro Devices Inc (Symbol: AMD) shares, but cautious about paying the going market price of $244.68/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December 2028 put at the $120 strike, which has a bid at the time of this writing of $16.85. Collecting that bid as the premium represents a 14% return against the $120 commitment, or a 4.9% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to AMD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $120 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Advanced Micro Devices Inc sees its shares fall 51.2% and the contract is exercised (resulting in a cost basis of $103.15 per share before broker commissions, subtracting the $16.85 from $120), the only upside to the put seller is from collecting that premium for the 4.9% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Advanced Micro Devices Inc, and highlighting in green where the $120 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the December 2028 put at the $120 strike for the 4.9% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Advanced Micro Devices Inc (considering the last 251 trading day closing values as well as today's price of $244.68) to be 59%. For other put options contract idea...

Massive capital flows from tech giants are transforming the nuclear energy sector into the critical backbone of the modern artificial intelligence economy.

Why Palantir Technologies Stock Charged Higher Today Nasdaq

稀土与关键矿产类股周二上涨，因欧盟势将向美国提议建立关键矿产伙伴关系。 个股方面：USA Rare Earth涨16%、United States Antimony涨15%、Critical Metals涨14%、MP Materials涨9.0%、NioCorp涨16%、TMC the metals company涨4.5%、Energy Fuels涨14%、Ramaco Resources涨8.9%、Trilogy Metals涨11%。 稀土股延续周一的涨幅。 责任编辑：李桐

Broadcom Inc. Announces Enterprise Wi-Fi 8 Access Point and Switch Solution for the AI Era marketscreener.com

NVIDIA (NVDA) Partners with Dassault Systemes for AI-Driven Indu GuruFocus

At the Annual General Meeting on 26 March 2026, the Board of Directors will propose a final dividend of DKK 7.95 per share for 2025, taking the expected total dividend for 2025 to 11.70. The Board of Directors has decided to initiate a new share repurchase programme of up to DKK 15 billion. Adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, is expected to be -5 to -13% at CER. Adjusted sales growth reported in Danish kroner is expected to be 3 percentage points lower than at CER. The sales outlook is impacted by lower realised prices, including impacts related to the "Most Favoured Nations" agreement in the US and the patent expiry of the semaglutide molecule in certain IO markets, as well as competition. The global GLP-1 market is expected to continue to expand with Novo Nordisk introducing new treatments, such as Wegovy ® pill and higher doses of Wegovy ® , enabling Novo Nordisk to continue to increase patient reach and expand volumes. Adjusted operating profit growth is expected to be -5 to -13% at CER. Adjusted operating profit growth reported in Danish kroner is expected to be 5 percentage points lower than at CER. Sales and operating profit for 2026 will be positively impacted by a reversal of sales rebate provisions of USD 4.2 billion related to the 340B Drug Pricing Program in the US. Key R&D developments in the quarter include the phase 2 trial with zenagamtide (previously amycretin) showing significant weight loss and HbA 1c reduction in type 2 diabetes, and the phase 3 trial REIMAGINE 2 with CagriSema, also in diabetes, was successfully completed. Within obesity, Novo Nordisk has submitted semaglutide 7.2 mg and the next-generation asset CagriSema to the US FDA. On 22 December, the US FDA approved the first oral GLP-1 in obesity, once-daily oral semaglutide 25 mg, under the brand name of Wegovy ® pill. Wegovy ® pill was launched on 5 January 2026, and as of 23 January, total weekly prescriptions amounted to around...

文章提及标的 伦敦金 -- 现货黄金日内涨幅扩大至7%，报4985.02美元/盎司。

NVIDIA (NVDA) Faces Continued Decline Amid Uncertainty Over Open GuruFocus

格隆汇2月4日｜现货黄金日内涨幅扩大至7%，报4985.02美元/盎司。

Europe must keep control of key technologies, says EU commissioner Reuters

迪士尼 （DIS）周二早盘下跌1.8%，该公司投资者静候董事会CEO人选；Bob Iger称抗拒变革是“错误”，同时乐园业务营收创纪录。 责任编辑：张俊 SF065

hapabapa AbbVie ( ABBV ) is expected to report a 23% surge in its fourth-quarter earnings, scheduled for February 4, before the opening bell. The company’s EPS is seen coming in at $2.65, while revenue is projected to jump 8.7% to $16.41B. In January, the company had said that it expects to incur acquired IPR&D and milestone expenses of $1.3B in its Q4 financial results, leading to a -$0.71 impact to GAAP and non-GAAP diluted EPS. The company said its Q4 diluted EPS guidance range, including the impact of the IPR&D and milestones expense, is $2.61-$2.65. Over the last 3 months, EPS estimates have seen no upward revisions but have witnessed 12 downward moves. Revenue estimates have seen 12 upward revisions and 2 downward moves. Analysts at Bernstein noted that the company has had a strong run-up this year, driven by growing recognition of Skyrizi and Rinvoq’s earnings potential, demonstrated by consistent quarterly beats. The company is expected to maintain the momentum. Going forward, IBD trial results will be critical for AbbVie because of intensifying competition in this treatment area. For instance, ABBV faces rising competition from JNJ’s ( JNJ ) Tremfya in IBD. 2026 is also expected to be a catalyst-rich year across AbbVie’s three core pillars- immunology, oncology, and neuroscience, Bernstein said. “We should expect to see more deals from AbbVie in 2026 as the company looks to augment growth in the early 2030s. In particular, they have signaled that they would like to complement the obesity asset they acquired from Gubra, an amylin, with a partner molecule,” it additionally noted. AbbVie is projected to guide 2026 in line with estimates but is likely to raise long-term guidance on Skyrizi/Rinvoq. Over the last 2 years, ABBV has beaten EPS estimates 63% of the time and has beaten revenue estimates 100% of the time. More on AbbVie AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript AbbVie: The Dividend Does Not Lie AbbVie: Roc...

Grandbrothers/iStock Editorial via Getty Images Prelude Therapeutics ( PRLD ) traded higher on Tuesday after the Wilmington, Delaware-based biotech received FDA clearance to advance an early-stage trial for its blood cancer candidate PRT12396 developed with Incyte ( INCY ). The company said that the agency greenlighted its Investigational New Drug Application for PRT12396, which is designed to target a group of blood cancers known as myeloproliferative neoplasms. The Phase 1 trial is expected to evaluate PRT12396 in high-risk polycythemia vera and intermediate and high-risk myelofibrosis, with its dosing expected to begin in Q2 2026. The open-label, multi-center study is designed to evaluate the safety and efficacy of the drug as some of its primary endpoints. PRT12396 is part of Prelude’s ( PRLD ) JAK2V617F JH2 inhibitor program, which represents candidates targeting a genetic mutation called JAK2V617F, the key factor leading to the progression of a majority of myeloproliferative neoplasms. More on Prelude Therapeutics, Incyte What Investors Should Know Before Buying Incyte Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Incyte: Buy For The Turnaround, Stay For The Pipeline Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy